Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-04 |
2024-09 |
0.06 |
N/A |
N/A |
N/A |
2024-08-14 |
2024-06 |
0.02 |
-0.03 |
-0.05 |
-250.00% |
2024-05-10 |
2024-03 |
0 |
-0.06 |
N/A |
N/A |
2024-03-14 |
2023-12 |
-0.03 |
-0.07 |
-0.04 |
-133.33% |
2023-11-06 |
2023-09 |
-0.07 |
-0.04 |
0.03 |
42.86% |
2023-08-07 |
2023-06 |
-0.04 |
0.21 |
0.25 |
625.00% |
Date |
Name |
Relation |
Quantity |
Description |
2024-03-31 |
BASHAN DROR |
Chief Executive Officer |
0.00 |
Stock Award(Grant) |
2016-12-01 |
CAMBER CAPITAL MANAGEMENT L L C |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2021-06-02 |
DEXCEL PHARMA TECHNOLOGIES, LTD. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2023-08-14 |
HAYON YAEL |
Officer |
0.00 |
Stock Award(Grant) |
2015-12-13 |
MAIMON YOSSI |
Chief Financial Officer |
195.00K |
Purchase |
2017-05-15 |
MANOR MOSHE |
Chief Executive Officer |
50.00K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
2.64M |
5.28M |
3.69% |
2023-06-29 |
State Street Corporation |
731.24K |
1.46M |
1.02% |
2023-06-29 |
Renaissance Technologies, LLC |
659.30K |
1.32M |
0.92% |
2023-06-29 |
Marshall Wace LLP |
562.14K |
1.12M |
0.79% |
2023-06-29 |
Geode Capital Management, LLC |
552.37K |
1.10M |
0.77% |
2023-06-29 |
Northern Trust Corporation |
362.91K |
725.83K |
0.51% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
iShares Russell 2000 ETF |
1.19M |
2.25M |
1.66% |
2023-07-30 |
Fidelity Small Cap Index Fund |
491.59K |
786.55K |
0.69% |
2023-08-30 |
iShares Russell 2000 Value ETF |
469.13K |
886.65K |
0.66% |
2023-07-30 |
TIAA-CREF Funds-Equity Index Fund |
176.99K |
283.19K |
0.25% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
155.00K |
310.00K |
0.22% |
2023-07-30 |
Schwab Capital Trust-Small Cap Index Fund |
128.42K |
205.47K |
0.18% |
Split |
Date |
1 : 10 |
2019-12-20 |
0.1 : 1 |
2007-01-03 |